Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enshuangping in obese adults with type 2 diabetes
ChiCTR2200066159Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin + rosiglitazone, metformin and empagliflozin in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Renji Hospital. Primary endpoints: Blood glucose, Visceral adipose tissue content and 6 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
metformin + rosiglitazonemetforminempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2200066159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066159.